BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:55 PM
 | 
Oct 18, 2017
 |  BC Extra  |  Company News

Management tracks: Gilead, Ipsen, Depomed

Gilead Sciences Inc. (NASDAQ:GILD) promoted Alessandro Riva to EVP of oncology therapeutics. He was SVP of hematology and oncology therapeutic area head. Before joining Gilead this year, he was head of global oncology development at Novartis AG (NYSE:NVS; SIX:NOVN).

Cancer company Ipsen Group (Euronext:IPN; Pink:IPSEY) promoted Dominique Laymand to EVP, chief ethics and compliance officer from SVP, chief ethics and compliance officer.

Pain company Depomed Inc. (NASDAQ:DEPO) named Santosh Vetticaden CMO, CSO and SVP. He...

Read the full 374 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >